HOME >> MEDICINE >> NEWS
Depression caused by common treatment for hepatitis C may affect outcome

ATLANTAAn article appearing in the January 2005 issue of Brain, Behavior and Immunity suggests that developing depression while on interferon-alpha plus ribavirin may impact how well the medications work.

In a study conducted in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, Charles L. Raison, MD, Andrew Miller, MD, and colleagues, observed that patients who develop depressive symptoms during interferon-alpha plus ribavirin therapy were significantly less likely to have cleared the hepatitis C virus from their blood following six months of treatment.

"Hepatitis C infection affects three to five million Americans, and is the leading cause of liver transplantation," said Dr. Raison. "With advances in treatment, 40-50 percent of patients can be cleared of the virus. Unfortunately, however, the current treatment for hepatitis C interferon-alpha plus ribavirin produces a high rate of psychiatric side effects that have long been recognized as impediments to successful antiviral therapy. In the past we primarily worried that depression interfered with quality of life, or would cause patients to stop taking the medicine. These new data suggest that even if patients stay on treatment, they are less likely to have a good outcome if they develop depression."

The study examined 103 participants who received pegylated interferon-alpha-2b plus ribavirin (PEG IFN/ribavirin). All participants were psychiatrically evaluated prior to initiation of the medication and at 4, 8, 12 and 24 weeks of PEG IFN/ribavirin treatment.

Only 34% of the patients who had a significant increase in depression cleared the hepatitis C virus from their blood at 24 weeks, as compared to 59%-69% of patients with milder increases in depression. The effect of depression on viral clearance persisted even after adjusting for factors known to affect treatment outcome, such as viral genotype, or whether medications had to
'"/>

Contact: Kathi Baker
kobaker@emory.edu
404-727-9371
Emory University Health Sciences Center
14-Jan-2005


Page: 1 2

Related medicine news :

1. Depression linked to insomnia in HIV patients
2. Depression may explain higher risk of heart attack associated with antidepressants
3. Depression predicts heart rhythm abnormalities in heart attack patients
4. Depression tied to higher risk of heart disease death
5. Depression predicts mortality in women with heart disease
6. Depression can lead to back pain
7. Depression on College Campuses conference
8. Depression may be a risk factor for heart disease, death in older women
9. Depression, other psychiatric illnesses common following traumatic brain injury
10. Depression, trauma stress linked to physical complaints
11. Depression doubles risk of death after bypass surgery

Post Your Comments:
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... virus that causes common cold sores -- herpes simplex -- ... Swedish researchers suggest. In fact, being a carrier of ... Alzheimer,s disease, the researchers found. "The identification of ... disorder is a breakthrough," said lead researcher Dr. Hugo Lovheim, ...
(Date:10/25/2014)... (HealthDay News) -- Researchers who discovered antibiotics in ... cause for concern. The use of antibiotics ... human consumption contribute to the development of antibiotic-resistant ... information from the study. Each year in ... million people and kill about 23,000, according to ...
(Date:10/25/2014)... (HealthDay News) -- Current osteoporosis screening guidelines and ... at risk for osteoporosis-related fractures, a new study ... we need tools that help us accurately predict ... we can target these at-risk people for preventive ... medicine in the division of general internal medicine ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- October,s shorter, darker days ... affective disorder, according to an expert. People ... feel overly tired, lack motivation and even have trouble ... lead to suicide, said Dr. Angelos Halaris, a professor ... Loyola University Chicago Stitch School of Medicine. "Seasonal ...
(Date:10/22/2014)... 22, 2014 On Saturday, October 25, 2014, ... annual family health and fitness fair ¡Vive tu vida! Get ... and good nutrition for better health and wellness for people ... free and open to the public, will be held at ... 9:00 am to 1:00 pm. , “¡Vive tu Vida! ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
(Date:10/25/2014)... -- Burzynski Research Institute, Inc. (BRI) announced today that ... the company permission to conduct an open-label study of ... of age with a diffuse intrinsic brainstem glioma (DIPG). ... treatment groups based on their age and whether or ... primary study endpoint is a decrease in the size ...
(Date:10/22/2014)... 2014  Cephasonics, a technology-innovation leader with a game-changing ... (cQuest Ultrasound Box™-1), the first product in a new ... by Cephasonics for purchase by companies to rebrand with ... be showcasing the cQUB-1 for the first time at ... Chongqing, China from October 23 to ...
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
Cached News: